ID   ACE2plusC3
AC   CVCL_D4Z5
SY   ACE2plusC3-A549/ACE2/TMPRSS2
DR   ATCC; CRL-3560
DR   Wikidata; Q127380199
RX   PubMed=35891350;
CC   Group: SARS-CoV-2 research cell line.
CC   Population: Caucasian.
CC   Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=35891350).
CC   Doubling time: ~24-36 hours (ATCC=CRL-3560).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; 13557; ACE2.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; 11876; TMPRSS2.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): ATCC=CRL-3560
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 14
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 02-05-24; Last updated: 10-09-24; Version: 2
//
RX   PubMed=35891350; DOI=10.3390/v14071369; PMCID=PMC9318744;
RA   Chang C.-W., Parsi K.M., Somasundaran M., Vanderleeden E., Liu P.,
RA   Cruz J., Cousineau A., Finberg R.W., Kurt-Jones E.A.;
RT   "A newly engineered A549 cell line expressing ACE2 and TMPRSS2 Is
RT   highly permissive to SARS-CoV-2, including the delta and omicron
RT   variants.";
RL   Viruses 14:1369.1-1369.14(2022).
//